- Analysis of non-life insurers' Solvency and Financial Condition Reports: European and Polish non-life insurers - Year-end 2016
By Marcin Krzykowski, Jarosław Lech | 23 April 2018
Our European analysis of the non-life market covers 140 companies from 11 countries, which together comprise more than €141 billion of gross written premium (GWP) and nearly €224 billion of gross technical provisions, and our Polish analysis is based on 14 solo companies pursuing non-life business in Poland, representing circa 89% of the GWP of the Polish non-life market in 2016.
- Analysis of life insurers' Solvency and Financial Condition Reports: European and Polish life insurers - Year-end 2016
By Marcin Krzykowski, Jarosław Lech | 23 April 2018
Our analysis of the European life insurance market covers 200 companies from 13 countries, representing approximately €475 billion in gross written premium and approximately €4,700 billion of gross technical provisions.
- Tweeting yourself out of a job: Do social media influencers need reputational risk insurance?
By Madeline Johnson | 20 April 2018
Individuals who rely on their name for income may have a need for some type of reputation risk or business interruption insurance, but could such a product exist?
- PRA’s Consultation Paper on modelling of the volatility adjustment for internal model firms
By Robert Bugg, Lyndsay Wrobel | 20 April 2018
The proposal to consider applications from internal model firms that include a Dynamic Volatility Adjustment is relevant to UK Solvency II firms and to the Society of Lloyd’s and its managing agents, and most relevant to firms with, or seeking, Volatility Adjustment approval and which use, or may develop in the future, a full or partial internal model to determine the Solvency Capital Requirement.
- How changing opioid prescribing patterns can impact risk scores
By Christine M. Mytelka, Melanie K. Kuester, Colin R. Gray, Lucas Everheart | 19 April 2018
This brief provides data on the decline in opioids prescribed to Medicaid expansion populations and the increased use of other non-opioid pain relief drugs.
- 2018 Corporate Pension Funding Study
By Zorast Wadia, Alan H. Perry, Charles J. Clark | 18 April 2018
During 2017, the private single-employer defined benefit plans of the Milliman 100 companies made significant funding improvements.
- Brexit: Beyond passporting: Implications for the UK insurance industry
By Kyle Audley, Jennifer Strickland, Fred Vosvenieks | 18 April 2018
This paper considers various future routes that the development of insurance regulation in the UK could take due to Brexit and the impact each of these might have on UK insurers.
- Providing adequate retirement income for employees through cash balance plans
By John B. Wukitsch, Neil Hagin | 17 April 2018
Milliman helps a regional financial services employer design a retirement program that would better meet its future needs.
- A “gold standard” for population health? Revisiting the FDA’s relationship with the Hippocratic Oath
By Gillian Woollett, Bruce S. Pyenson | 16 April 2018
The Food and Drug Administration should use a population health context to meet 21st century expectations for pharmaceutical risk.
- The exclusion of some nursing facility visits from MSSP assignment has potential unintended consequences
By Tia Goss Sawhney, Kathryn V. Fitch, Cory Gusland | 16 April 2018
This article describes the changes in the historical benchmarks and performance expenditures for a number of Medicare Shared Savings Program accountable care organizations and also explains the possible impact of these changes.